Last Updated: 18/06/2024
Understanding the mechanism of the African-type Artemisinin resistance of Plasmodium falciparum
Objectives
The purpose of this study is to identify the gene determining K13-independent African artemisinin resistance in malaria parasites, which is still unclear by conducting a clinical artemisinin resistance investigation in Kenya, isolate artemisinin-resistant protozoa without the resistant K13 mutation from patients who have shown resistance, and perform linkage analysis by crossing with susceptible strains.
Plasmodium falciparum resistant to artemisinin, a first-line antimalarial drug, has emerged in Southeast Asia due to a mutation in a gene called K13. On the other hand, malaria was recently reported in Africa with artemisinin resistance despite the absence of K13 mutations. A Japanese researcher traveled to Kenya in May to conduct a field survey and collect new protozoan strains, but due to the outbreak of the COVID-19 Omicron strain that began at the end of 2021, travel was not possible. Therefore, among the Plasmodium falciparum culture strains obtained so far in Kenya, for protozoa that show resistance that cannot be explained by known drug-resistant mutations, in order to verify the mutation that is thought to be the cause, production of genetically modified protozoa advanced. In addition, there was a problem with the rearing of vector mosquitoes for the malaria parasite mating experiment that had been prepared, so new vector mosquitoes were botained from overseas and established internal regulations, etc. regarding the infection of pathogens to arthropods.
Oct 2019 — Mar 2023
$158,351
Related Resources
